Takhzyro under the microscope: Real-World safety check for rare swelling disease
NCT ID NCT07445087
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how safe and effective Takhzyro is for teenagers and adults with hereditary angioedema (HAE) in everyday medical care in South Korea. HAE is a rare condition that causes sudden swelling under the skin or inside the body. The study will track side effects and how well the drug prevents attacks. It involves 35 participants and follows their normal treatment routines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Takhzyro (lanadelumab)
- What this could lead to
- If successful, this study will confirm that Takhzyro is safe and works well for preventing swelling attacks in people with hereditary angioedema in real-world settings.
- What could go wrong
- This is a small, non-interventional study with only 35 participants, so results may not apply to everyone. It is designed to monitor safety, not to prove new benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder
- New shot could stop painful swelling attacks in kids